Growing Capital Pressure For Chinese Drug Firms From Overdue Debt
This article was originally published in PharmAsia News
Executive Summary
China’s growth rate of overdue institutional debt of pharma companies will recede by 2-3 percentage points to 15-18% this year, thus further intensifying capital pressure, forecasts the Ministry of Commerce.